MDMA Dosage Guide: What Is a Safe Dose of Molly or Ecstasy?

This MDMA (molly/ecstasy) dosage guide starts with the most important principle: the dose that feels modest for one person can be dangerously high for another. MDMA has non-linear pharmacokinetics, meaning a small increase in dose produces a disproportionately large increase in blood levels and adverse effects. Understanding what “a safe dose of ecstasy” actually means requires understanding that relationship, not just memorizing a number.

Quick answers

What is a safe dose of MDMA? For most adults, 75–125 mg taken orally is the range cited across harm reduction organizations. A body-weight-based rule of thumb is 1–1.5 mg/kg, capped at 120 mg. The Phase 3 clinical trials used 80 mg as the starting dose and 120 mg as the higher therapeutic dose. First-time users should start at the low end: 75 mg or less.

How much MDMA is too much? There is no universal threshold, but doses above 150 mg substantially increase cardiovascular strain, hyperthermia risk, and potential for serotonergic toxicity. Because of non-linear pharmacokinetics, going from 100 mg to 150 mg is not a 50% increase in effect, it produces a much steeper rise in plasma concentration. Many pressed pills contain 150–250 mg per pill, which exceeds the recreational dose before you’ve even redosed.

Do people redose? Harm reduction guidelines suggest at most once, at half the original dose (40–60 mg), no earlier than 90 minutes after the first dose. More than one redose significantly extends duration, increases total drug exposure, worsens the next-day comedown, and amplifies adverse effects. The active metabolite MDA has a longer half-life and peaks later, meaning you may not feel a second redose fully until it’s already compounded.

How do I know what’s in my pill? You don’t, without testing. Reagent testing and fentanyl test strips are essential, see our drug testing guide.

What clinical research uses as doses

The most rigorously controlled MDMA dosing data comes from the MAPS Phase 3 trials for PTSD treatment. Mitchell et al. 2021 (Nature Medicine, PMID 33972795) used the following protocol:

• Session 1: 80 mg initial dose + 40 mg supplemental dose 1.5–2.5 hours later
• Sessions 2 and 3: 120 mg initial dose + 60 mg supplemental dose

These are the most carefully monitored MDMA doses in any published human study. The 80 mg starting dose and 120 mg higher dose bracket what the clinical literature considers a therapeutically active range. At these doses, in a controlled setting with medical supervision, MDMA was found safe enough to administer to people with severe PTSD, including those with comorbid cardiovascular risk factors.

What this means for recreational use: the clinical anchor is not “120 mg is totally safe”, it’s that 80–120 mg is the range where therapeutic benefit was achieved with an acceptable adverse effect profile under controlled conditions. Recreational settings, hot clubs, dancing, alcohol, no medical monitoring, introduce risk factors that clinical settings eliminate entirely.

The weight-based approach

The community harm reduction standard for MDMA dosing is 1–1.5 mg/kg body weight, with most sources recommending a cap of 120 mg regardless of body weight. In practice:

This guideline is not RCT-validated, it comes from clinical pharmacology reasoning and community experience, not a randomized controlled trial. What it does reflect is the general principle that pharmacological effects scale with body mass, and that there’s a ceiling above which the risk-benefit ratio deteriorates.

First-time ecstasy dose: harm reduction guidelines suggest 75 mg or the low end of the weight-based range, whichever is lower. You can always take more; you cannot undo having taken too much. First experiences often feel more intense because there is no prior tolerance, and anxiety itself can amplify cardiovascular effects.

Why lower doses are genuinely safer: non-linear pharmacokinetics

This is the key concept that most dosing guides underemphasize.

De la Torre et al. 2000 (British Journal of Clinical Pharmacology, PMID 10671903) demonstrated that MDMA pharmacokinetics are non-linear: as the administered dose increases, MDMA plasma concentrations rise disproportionately, far more than a linear relationship would predict. Going from 75 mg to 150 mg is not a doubling of blood levels; it produces a much steeper climb because MDMA saturates its own metabolic enzyme (CYP2D6) and inhibits its own breakdown.

The practical consequence: a small dose increase produces an outsized spike in plasma concentration and adverse effects. The authors explicitly noted this makes subjects “more prone to develop acute toxicity” from what might seem like modest increases.

A related point: after two consecutive doses, MDMA causes mechanism-based inhibition of CYP2D6, making everyone, regardless of their genetic CYP2D6 phenotype, behave like a “poor metabolizer” (PMID 15228154). Poor metabolizers accumulate significantly higher plasma MDMA levels from the same dose. This is part of why redosing is pharmacologically riskier than the mg numbers suggest, and why some people have unexpectedly intense or prolonged responses.

The dose-response relationship for adverse effects, hyperthermia, cardiovascular strain, serotonin syndrome risk, scales with this non-linearity. This is why harm reduction organizations and clinical researchers converge on keeping doses below 125 mg rather than treating higher doses as simply “stronger.”

The pressed pill problem

Pressed pills are one of the most dangerous variables in recreational MDMA use, for two reasons: unknown dose and unknown content.

Drug checking databases consistently show that pressed ecstasy tablets span an enormous range, from pills containing no MDMA at all to pills containing 200 mg or more. Drug checking databases, including data compiled by Palamar and colleagues, have found pill content ranging from 0 to over 240 mg per tablet. A single “normal-looking” pill may contain 180 mg, already above the safe recreational range before any redosing, while a different pill from the same batch may contain 80 mg. You cannot tell by looking, and the tablet is often inconsistently mixed, meaning the first half and second half of the same pill may have different MDMA concentrations.

The second problem is adulterants. Common substitutes and additions found in drug checking include:

• Methamphetamine: produces similar stimulant effects but has a much longer half-life, higher addiction potential, and distinct neurotoxicity profile
• Synthetic cathinones (methylone, MDPV, mephedrone), unpredictable duration, lower therapeutic index
• Fentanyl: confirmed in MDMA samples at multiple festival drug checking operations; lethal at microgram doses

Testing your supply before dosing is not optional if you care about safe dosing. A reagent test (Marquis + Simon’s reagents) tells you whether MDMA is the primary active substance. A fentanyl test strip tells you whether fentanyl is present. The DanceSafe complete 9-kit testing set covers all the reagents you need. Use both before every session, not just once.

See our drug testing guide for the full step-by-step testing protocol.

Redosing rules

If you redose, follow these rules, all of them, not just some:

1. One redose only. A second redose dramatically increases total drug exposure and adverse effects without proportionally increasing the desired effects. The dose-response curve for euphoria flattens; the curve for adverse effects does not.
2. Half the original dose. If you took 100 mg, the redose is 50 mg. No more.
3. Wait at least 90 minutes. Peak MDMA plasma concentrations occur around 1.5–2 hours after oral dosing. Redosing before this point stacks on top of a still-rising first dose.
4. Account for MDA. MDMA is partially metabolized to MDA, an active metabolite with a longer half-life. MDA peaks later than MDMA. When you redose, MDA from the first dose is still building, the true pharmacological load is higher than the MDMA mg alone suggests.

Individual factors that affect MDMA response

Two people can take the same dose and have substantially different experiences and risk profiles:

CYP2D6 genetics. MDMA is metabolized primarily by the liver enzyme CYP2D6. Approximately 5–10% of people of European descent are CYP2D6 “poor metabolizers”, they break down MDMA much more slowly, leading to higher plasma concentrations from the same dose. This is not something you can determine without genetic testing, which is why starting low matters even more for first-time users.

Body temperature and environment. Hyperthermia is one of the most reliably dangerous MDMA risk factors. Hot dance environments, physical exertion, and inadequate hydration significantly increase the risk of dangerous core temperature elevation. MDMA impairs thermoregulation. This is not a theoretical risk, MDMA-related fatalities are disproportionately associated with hyperthermia, not cardiac events in isolation.

Drug combinations. MDMA with MAOIs can cause fatal serotonin syndrome. MDMA with other serotonergic substances (including some antidepressants) significantly amplifies serotonin toxicity risk. MDMA with stimulants compounds cardiovascular strain. For a full breakdown, see our interaction checker.

Hydration status. Both too little and too much water create risk. MDMA can cause hyponatremia (dangerously low sodium) if you drink excessive plain water without electrolytes, particularly in women. The guideline is approximately 500 mL (about 16 oz) of water per hour of dancing, with electrolyte replacement. If you are not dancing, drink to thirst.

First-time user checklist

• Test the substance with at least Marquis + Simon’s reagents and a fentanyl test strip before taking anything
• Dose conservatively: 75 mg or less for a first experience; use the weight-based formula and take the lower estimate
• Know what you weigh and calculate your 1 mg/kg dose as a reference ceiling
• Don’t redose the first time: evaluate how a single dose feels before deciding whether redosing is even something you want to do
• Manage temperature: take breaks from dancing, spend time in cooler areas, don’t wear excessive layers
• Drink appropriately: water with electrolytes, not excessive plain water
• Don’t combine with alcohol, SSRIs, or stimulants without understanding the interactions, check our interaction guide first
• Have a trusted person with you who knows what you took and can get help if needed

MDMA dose is one of the most controllable harm reduction variables, and one of the most frequently ignored. The clinical trials, the pharmacokinetics research, and community harm reduction experience all point to the same conclusion: the 75–120 mg range, properly weight-adjusted, tested for content, taken once without heavy redosing, in a cool environment with adequate hydration, represents the lowest achievable risk profile for recreational MDMA use.

For the full picture of MDMA effects, risks, and harm reduction strategies, see our MDMA guide.

Sources: PMID 33972795 | PMID 10671903 | PMID 15228154 | PMID 21320226